conditioning regimen consisted of TBI and high-dose Ara-C with G-CSF as previously reported. 1 CsA with short-term MTX was used as GVHD prophylaxis. Transient grade I A 41-year-old female patient with AML, who relapsed after an allogeneic BMT from her HLA-identical sister, acute GVHD occurred and the AML relapsed on day 129 after the BMT with 12% leukemic blasts in the BM. After was treated by a donor leukocyte transfusion (DLT). Thereafter, bone marrow aplasia accompanied by the the discontinuation of CsA, 1.1 × 10 8 /kg donor peripheral blood mononuclear cells were administered on day 158. disappearance of leukemic blasts following the GVHD was observed. The patient died of chronic GVHD with Thereafter, the leukemic blasts rapidly disappeared from her BM. Skin GVHD developed about 2 months after the respiratory muscle involvement 19 months after the DLT. Although the DLT was considered helpful in sup-DLT and was successfully controlled with prednisolone and CsA. Although her BM remained hypocellular and she was pressing the proliferation of the leukemic cells, it might also have caused the severe GVHD observed in this case. dependent on weekly platelet and red cell transfusions, all detectable blood DNA samples turned to donor origin on Efforts to separate the lymphocyte clones responsible for GVL from those for the GVHD thus appear to be day 289 after DLT determined by PCR of variable number of tandem repeat sequences (VNTR). She was admitted to necessary for the further development of the therapeutic approach, so-called DLT.
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other organs showed no evidence of any viral particles and no inclusion bodies, respectively.
Discussion
This case satisfactorily fulfilled the four major criteria used to define myositis. 2 The first is a symmetrical weakness of the limb muscles progressing over months with respiratory muscle involvement. The second is histologic evidence of necrosis of muscle fibers, atrophy and inflammatory exudate. The third is an elevation of skeletal-muscle enzymes in the serum such as creatine kinase, aldolase, glutamate oxaloacetate, pyruvate transaminases and lactate dehydrogenase. The fourth is an electromyographic triad of short, myositis or dermatomyositis associated with neoplasia, 3 while no evidence of neoplasia was seen except for the underlying disease in the present case. After the DLT, repeated examinations of peripheral blood and BM revealed the diaphragm and muscles in the lower limbs. All efforts to identify a viral infection such as elevation of antibodies no evidence of relapse and the VNTR findings showed blood samples of donor origin. As a result, mononuclear to Coxsackie virus A2, A3, A7, A16, B1, polymerase chain reaction to virus DNA for Epstein-Barr virus, cytomegalocells infiltrating the muscles were thus considered to have originated from the donor. In addition, generalized infilvirus and human herpes virus 6 and cultures for viruses were negative. Electron microscopic examinations of autotration of the mononuclear cells were also observed, thus indicating chronic GVHD in spite of the long term use of psied muscle specimens and microscopic examinations of immunosuppressants. Accordingly the myositis is thus conmanifestation of chronic GVHD that can sometimes be fatal. When myositis is suspected, such invasive examinsidered to be one manifestation of chronic GVHD.
Myositis has been reported as a late component of ations such as an EMG and a muscle biopsy should be done immediately to establish a definitive diagnosis, and the GVHD after allogeneic BMT. To our knowledge, there have been 18 previously reported cases of muscle GVHD immunosuppressive treatment should also be started before muscle weakness becomes too severe. As there are still no as shown in Table 2 . Myositis occurred mainly in non-leukemic patients before 1988 and mainly in leukemic patients established treatment regimens for muscle GVHD, the primary goal of such treatment is to control the extended after 1991. This tendency is significant (P = 0.0118, metaanalysis with Fisher's exact probability test). This phenomchronic GVHD. Corticosteroids, CsA, azathioprine, CY and ATG are used to treat chronic GVHD. Recently developed enon is interesting but its significance remains to be clarified. Two cases did not demonstrate acute GVHD. The immunosuppressive agents such as FK506 or 15-deoxyspergualin may also help to control extended chronic intervals from BMT to onset of muscle GVHD varied from 3 to 54 months (mean Ϯ s.d. = 17.0 Ϯ 15.7 months). Most GVHD that proves to be resistant to conventional immunosuppressants. Since our patient died of GVHD, it is postucases of muscle GVHD developed at chronic phases and so far, none have reported muscle GVHD to be the cause lated that she most likely needed more intensive treatment for GVHD. On the other hand, some of the reported cases of death. We consider this to be the first case of muscle GVHD including respiratory failure. Muscle GVHD is a died of infections thus suggesting that intensive immunosuppressive treatments may also lead to a higher risk of rare complication which may also occasionally be fatal. Once muscle atrophy has been completed, it might be very infection.
Despite the fact that only a small number of individuals difficult for such muscle tissue to recover even if the inflammations can be well controlled. Table 2 suggests that have been treated with DLT at the present time, muscle GVHD was observed to occur in three of 19 cases after those who were treated before their muscle weakness became severe had a good outcome. We therefore rec-DLT (Table 2) . 4, 5 It is thus suggested that T cells in the donor's peripheral blood may have the potential to cause ommend clinicians to recognize myositis as a possible develop new therapeutic approaches.
